In the News
TIME: The 100 Most Influential People
No one, not even a bacterium, likes being infected by a virus, and early in evolution, bacteria developed a way to destroy viruses with exquisitely precise attacks. Very recently, Emmanuelle Charpentier and Jennifer Doudna figured out the inner workings of this bacterial self-protection, and then, in a tour de force of elegant deduction and experiment, they developed a plug-and-play version of that approach.
FierceBiotech: Novartis steps in to help bankroll CRISPR-Cas9 pioneer Caribou
Pharma heavyweight Novartis has stepped in to help bankroll Berkeley, CA-based Caribou Biosciences, one of the upstart leaders in the race to develop the cutting-edge CRISPR-Cas9 gene editing technology.
Xconomy: Doudna’s Caribou Bio Raises $11M To Expand Uses For Gene Editing Tech
Caribou Biosciences, one of the biotech startups working to advance a much-watched new technology for precise gene editing, announced today it has raised an $11 million Series A round from venture capital firms and Swiss drug giant Novartis.
Nature Biotechnology: Nature Biotechnology's academic spinouts of 2014
Ventures focusing on drug testing or therapies against rare disease, cancer, gastrointestinal disease, fibrosis and pain are among those selected by the editors in 2014's crop of startups.
Reuters: Novartis taps into gene editing for next generation drugs
Novartis is diving deeper into the world of gene-based medicine by signing deals with two U.S. biotech companies, giving it access to a powerful new genome editing technology.